匹立昔尔 | 65089-17-0

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 匹立昔尔
• 英文名称: <<4-chloro-6-<(2,3-dimethylphenyl)amino>-2-pyrimidinyl>thio>-N-(2-hydroxyethyl)acetamide
• 英文别名: 2-(4-chloro-6-(2,3-xylidino)pyrimidin-2-ylthio)-(N-β-hydroxyethyl)acetamide；BR931；2-[4-chloro-6-(2,3-dimethyl-anilino)-pyrimidin-2-ylsulfanyl]-N-(2-hydroxy-ethyl)-acetamide；[4-chloro-6-(2,3-xylidino)-2-pyrimidinyl-thio]-(N-β-hydroxyethyl)-acetamide；Pirinixil；2-[4-chloro-6-(2,3-dimethylanilino)pyrimidin-2-yl]sulfanyl-N-(2-hydroxyethyl)acetamide
• CAS: 65089-17-0
• 化学式: C₁₆H₁₉ClN₄O₂S
• 分子量: 366.871
• InChiKey: RZCKTPORLKUFGY-UHFFFAOYSA-N

物化性质

• 熔点：
  145°C
• 沸点：
  609.6±55.0 °C(Predicted)
• 密度：
  1.2894 (rough estimate)
• 溶解度：
  溶于二甲基亚砜

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  24
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.31
• 拓扑面积：
  112
• 氢给体数：
  3
• 氢受体数：
  6

安全信息

• 储存条件：
  2-8℃

制备方法与用途

生物活性

Pirinixil 是一种低毒性降血脂药。

体内研究

在实验中，Pirinixil 能显著降低大鼠脾脏、肾脏和心脏中的总胆固醇水平。它大约减少全身胆固醇总量的 40%。Pirinixil 显著提高血浆胆固醇水平而不影响血浆甘油三酯。肝脏中的胆固醇和甘油三酯明显减少，同时联合血浆和肝脏脂质水平下降约 20%。尽管如此，肝脏中 HMG-CoA 还原酶的活性未受影响，但胆固醇 7α-羟化酶显著降低。

反应信息

• 作为反应物：
  描述：

  匹立昔尔 在 sodium nitrite 作用下， 以 水 、 溶剂黄146 为溶剂， 反应 0.5h， 以70.7%的产率得到<<4-chloro-6--2-pyrimidinyl>thio>-N-(2-hydroxyethyl)acetamide
  参考文献：
  名称：

  Novel pyrimidine and 1,3,5-triazine hypolipemic agents

  摘要：

  New compounds were synthesized by changing the substituents of a trisubstituted pyrimidine, i.e., [[4-chloro-6-[(2,3-dimethylphenyl)amino]-2-pyrimidinyl]thio] acetic acid, a potent hypolipidemic agent, impaired, however, by a marked hepatomegaly-inducing effect. The structural variations led to the subsidence (14b, i.e., 4-chloro-2-(dimethylamino)-6-[(2,3-dimethylphenyl)amino]pyrimidine) or to the reduction (18b, [[4-chloro-6-[(2,3-dimethylphenyl)amino]-2-pyrimidinyl]amino] acetic acid) of said untoward effect but still maintained the hypolipidemic effect that, although markedly decreased, still proves significant for serum cholesterol and triglycerides (18b) or for serum triglycerides only (14b).

  DOI：

  10.1021/jm00378a016
• 作为产物：
  描述：

  ethyl <<4-chloro-6-<(2,3-dimethylphenyl)oxy>-2-pyrimidinyl>thio>acetate 在 sodium hydroxide 作用下， 以 乙醇 、 氯仿 为溶剂， 反应 16.03h， 生成 匹立昔尔
  参考文献：
  名称：

  Novel pyrimidine and 1,3,5-triazine hypolipemic agents

  摘要：

  New compounds were synthesized by changing the substituents of a trisubstituted pyrimidine, i.e., [[4-chloro-6-[(2,3-dimethylphenyl)amino]-2-pyrimidinyl]thio] acetic acid, a potent hypolipidemic agent, impaired, however, by a marked hepatomegaly-inducing effect. The structural variations led to the subsidence (14b, i.e., 4-chloro-2-(dimethylamino)-6-[(2,3-dimethylphenyl)amino]pyrimidine) or to the reduction (18b, [[4-chloro-6-[(2,3-dimethylphenyl)amino]-2-pyrimidinyl]amino] acetic acid) of said untoward effect but still maintained the hypolipidemic effect that, although markedly decreased, still proves significant for serum cholesterol and triglycerides (18b) or for serum triglycerides only (14b).

  DOI：

  10.1021/jm00378a016

文献信息

• (2-Pyrimidinyl-thio)-alkanoic acid amides and their preparation
  申请人：L'Instituto Farmaceutico S.p.A.

  公开号：US04188484A1

  公开（公告）日：1980-02-12

  The invention provides novel amides of (2-pyrimidinyl-thio)-alkanoic acids having antilipemic activity combined with a lower toxicity than the corresponding acids.

  本发明提供了(2-嘧啶基硫基)脂肪酸的新型酰胺，具有抗脂质血症活性，且比相应的脂肪酸毒性更低。
• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
  申请人：Counts David F.

  公开号：US10463611B2

  公开（公告）日：2019-11-05

  The present disclosure provides a once-daily water-soluble pharmaceutically active formulation for oral administration. In certain embodiments, the composition comprises a water-soluble pharmaceutically active organic compound incorporated into a small particulate, each particulate having a core of the water-soluble pharmaceutically active organic compound or an acceptable salt thereof in reversible association with a pharmaceutically acceptable drug-binding polymer. The core of the composition being surrounded by an insoluble water permeable membrane that is capable of delaying the dissolution of the pharmaceutically active compound therewithin and providing for extended release of the pharmaceutically active compound. In some embodiments, the formulation of the invention are designed to extend release of the pharmaceutically active organic compound for about 3 hours to about 8 hours, thereby enabling preparation of an extended release formulation for any pharmaceutically active compound with a half-life of from about 16 hours to about 21 hours.

  本公开提供了一种用于口服的每日一次水溶性药用活性制剂。在某些实施方案中，该组合物包括掺入小颗粒中的水溶性药用活性有机化合物，每个颗粒都有一个水溶性药用活性有机化合物或其可接受盐的核心，该核心与药学上可接受的药物结合聚合物可逆结合。组合物的核心由不溶性透水膜包围，该膜能够延迟其中的药用活性化合物的溶解，并延长药用活性化合物的释放时间。在某些实施方案中，本发明的制剂可将药用活性有机化合物的释放时间延长约 3 小时至约 8 小时，从而能够制备半衰期为约 16 小时至约 21 小时的任何药用活性化合物的缓释制剂。
• DATRI, G.;GOMARASCA, P.;RESNATI, G.;TRONCONI, G.;SCOLASTICO, C.;SIRTORI, +, J. MED. CHEM., 1984, 27, N 12, 1621-1629
  作者：DATRI, G.、GOMARASCA, P.、RESNATI, G.、TRONCONI, G.、SCOLASTICO, C.、SIRTORI, +

  DOI：——

  日期：——
• 4-BIARYLYL-1-PHENYLAZETIDIN-2-ONE GLUCURONIDE DERIVATIVES FOR HYPERCHOLESTEROLEMIA
  申请人：Microbia, INC.

  公开号：EP1877067A1

  公开（公告）日：2008-01-16